Clinical trials: Financial Stress
Psychological Stress, Anxiety
NeuroFinance Human Stress Trial During Financial and Informational Volatility
The NeuroFinance Human Stress Trial (NFHST-2026-001) is a decentralized observational clinical study designed to evaluate how financial market volatility, economic uncertainty, digital media exposure, and information-driven…
- Conditions
- Psychological Stress, Anxiety, Emotional Stress, Autonomic Nervous System Dysfunction
- Trial name
- NFHST (NCT07622589)
- Testing
- Wearable Physiologic Monitoring Platform
- Where
- United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Menopause, Perimenopausal Disorder
Virtual perI-/Menopause Registry of AusTrALia
13 million (50.7%) Australians are born with ovaries, 14% (~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as >12 months without a period.
- Conditions
- Menopause, Perimenopausal Disorder, Postmenopausal Symptoms, Health Knowledge, Attitudes, Practice
- Trial name
- VITAL (NCT06487130)
- Testing
- N/A Observational Registry
- Where
- Australia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Bespoke Clinical Research
Monocarboxylate Transporter 8 (MCT8) Deficiency, Allan-Herndon-Dudley Syndrome
MCT8 Deficiency Caregiver Study
Caregivers face many responsibilities outside of their role as a friend or parent, which can lead to emotional, financial, social, and professional challenges.
- Trial name
- NCT06060197
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Rare Thyroid Therapeutics International AB
Carcinoma, Renal Cell
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
Information on the prevalence of advanced/metastatic renal cell carcinoma and its symptom burden is limited in commercially insured adult patients.
- Trial name
- NCT01381601
- Testing
- Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Renal Cell
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
Information on the prevalence of advanced/metastatic renal cell carcinoma and its symptom burden is limited in commercially insured patients (age >= 18 years and < 65 years).
- Trial name
- NCT01381614
- Testing
- Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline